GlassScriptPhysician profile
Carmelo Herrero
NPI 1619078607
$9,316.88
in general payments reported to CMS, 2019-2025
39 companies · $750 in 2025
The $750 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,004 · 2020: $859 · 2021: $1,227 · 2022: $1,212 · 2023: $2,694 · 2024: $1,571 · 2025: $750.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,257 · Travel and Lodging: $742 · Education: $16.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,256.63 |
| Travel and Lodging | $741.94 |
| Education | $16.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,450.10 | 2019-2025 | |
| Janssen Biotech, INC. | $1,230.93 | 2019-2025 | Stelara, Tremfya, Simponi |
| Boston Scientific Corporation | $956.29 | 2019-2025 | Watchman Flx |
| Pfizer INC. | $504.57 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $391.15 | 2019-2024 | Entyvio, Gattex |
| Gilead Sciences, INC. | $352.39 | 2019-2024 | |
| Endogastric Solutions, INC | $347.63 | 2019-2023 | Esophyx |
| Ferring Pharmaceuticals INC. | $347.53 | 2019-2024 | Rebyota |
| Merck Sharp & Dohme LLC | $250.36 | 2020-2024 | Dificid, Zerbaxa |
| Celgene Corporation | $247.16 | 2023-2024 | Zeposia |
| Genzyme Corporation | $237.16 | 2023-2025 | |
| Intercept Pharmaceuticals, INC. | $177.74 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $163.88 | 2019-2025 | Xifaxan |
| Qol Medical, LLC | $160.46 | 2019-2025 | Sucraid |
| Nestle Healthcare Nutrition INC. | $144.69 | 2021-2023 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $132.69 | 2023 | Terlivaz |
| Smith+Nephew, INC. | $130.50 | 2022 | |
| Cook Medical LLC | $119.79 | 2019 | |
| Redhill Biopharma INC. | $112.92 | 2020-2023 | Talicia |
| Regeneron Healthcare Solutions, INC. | $81.01 | 2022-2025 | Dupixent |
| Lilly USA, LLC | $77.45 | 2023-2025 | Omvoh |
| Ambu INC. | $77.23 | 2020 | |
| Lucid Diagnostics INC. | $63.09 | 2021-2023 | |
| Madrigal Pharmaceuticals | $57.93 | 2025 | Rezdiffra |
| Ucb, INC. | $56.77 | 2019 | |
| Capsovision, INC. | $51.72 | 2025 | Capsocam Plus |
| Phathom Pharmaceuticals, INC. | $47.39 | 2024-2025 | Voquezna |
| Shionogi INC | $46.79 | 2019 | |
| Intra-Sana Laboratories | $41.65 | 2021 | |
| Aimmune Therapeutics, INC. | $40.09 | 2024-2025 | Zenpep |
| Organon LLC | $39.13 | 2023-2024 | Hadlima |
| Ironwood Pharmaceuticals, INC | $35.02 | 2021-2023 | Linzess |
| Conmed Corporation | $29.04 | 2019 | |
| Braintree Laboratories, INC. | $27.83 | 2020-2022 | |
| Dova Pharmaceuticals | $25.93 | 2019 | |
| Pharmacosmos Therapeutics INC. | $20.01 | 2022 | |
| Novo Nordisk INC | $16.85 | 2025 | Wegovy |
| Exact Sciences Corporation | $15.90 | 2023 | Cologuard Collection Kit |
| Echosens North America, INC. | $8.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carmelo Herrero listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.